NCT03568968CompletedPhase 3
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease: the NOPARK Study
Source: ClinicalTrials.gov · Last updated 26 Sept 2025
Brief summary (registry, in English)
NOPARK is a double-blinded randomized controlled phase II trial, with the aim to assess the efficacy of nicotinamide adenine dinucleotide (NAD)-replenishment therapy in the form of oral nicotinamide riboside (NR) in delaying the progression of early Parkinson's disease (PD). A total of 400 persons with early stage Parkinson's disease will be enrolled, randomized on nicotinamide riboside (NR) 500mg x 2 per day or placebo, and followed for 52 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 410 (actual)
- First submitted
- 14 Jun 2018
- Start date
- 6 May 2020
- Primary completion date
- 17 Jun 2025
- Lead sponsor
- Haukeland University Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT03568968
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 410
- From 6 May 2020 to the primary completion date, 17 Jun 2025
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Dementia or other neurodegenerative disorder at baseline visit
- Any psychiatric disorder that would interfere with compliance in the study.
- Any severe somatic illness that would make the individual unable to comply and participate in the study.
- Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit.
- Genetically confirmed mitochondrial disease
Other
- Diagnosed with atypical parkinsonism or vascular parkinsonism
- Use of high dose vitamin B3 supplementation within 30 days of enrolment
Who the study is looking for
- Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic criteria for Parkinson's disease
- \[¹²³I\]FP-CIT single photon emission CT (DaTscan) confirming nigrostriatal degeneration
- Diagnosed with PD within 2 years from enrolment
- Hoehn and Yahr score \< 3 at enrolment
- Optimal symptomatic therapy, not requiring adjustments, for at least 1 month.
- Age equal to or greater than 35 years at time of enrolment.
Age in the registry: 35 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Arendal Hospital Coordinator of this site? Confirm its status | Arendal | Norway | Unknown status |
| Haukeland University Hospital Coordinator of this site? Confirm its status | Bergen | Norway | Unknown status |
| Bodø Hospital Coordinator of this site? Confirm its status | Bodø | Norway | Unknown status |
| Vestre Viken Hospital Coordinator of this site? Confirm its status | Drammen | Norway | Unknown status |
| Førde sykehus Coordinator of this site? Confirm its status | Førde | Norway | Unknown status |
| Østfold Hospital Coordinator of this site? Confirm its status | Fredrikstad | Norway | Unknown status |
| Haugesund Hospital Coordinator of this site? Confirm its status | Haugesund | Norway | Unknown status |
| Molde Sjukehus Coordinator of this site? Confirm its status | Molde | Norway | Unknown status |
| Oslo University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Unknown status |
| Akershus University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Unknown status |
| University Hospital of North Norway Coordinator of this site? Confirm its status | Tromsø | Norway | Unknown status |
Related publications
- Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.JAMA · 2026 · PMID 42848371
This page is information, not medical advice. Discuss any trial with your doctor.